Erdheim Chester Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for erdheim chester disease. 6 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
6
Active US patents
35/100
Avg vulnerability
$100M
Annual revenue covered

Originators in Erdheim Chester Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Hoffmann La Roche 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating erdheim chester disease. Each bar = one year. Y-axis scaled to peak year (3 patents).

3
26
1
29
1
30
1
32

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Zelboraf
vemurafenib
 Hoffmann La Roche 6 35 $100M 2026-06-21

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8470818 Zelboraf method of use 85 2026-08-02
9447089 Zelboraf formulation 42 2032-06-06
8143271 Zelboraf composition of matter 27 2026-06-21
7504509 Zelboraf composition of matter 27 2026-10-22
7863288 Zelboraf composition of matter 15 2029-06-20
8741920 Zelboraf composition of matter 15 2030-07-27

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8741920 Zelboraf composition of matter 15 2030-07-27
7863288 Zelboraf composition of matter 15 2029-06-20
7504509 Zelboraf composition of matter 27 2026-10-22
8143271 Zelboraf composition of matter 27 2026-06-21
9447089 Zelboraf formulation 42 2032-06-06
8470818 Zelboraf method of use 85 2026-08-02

Related